Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice

Skeletal Muscle

Volumn 3, Issue 1, 2013, Pages

  Ieronimakis, Nicholas ^a   Pantoja, Mario ^b   Hays, Aislinn L ^a   Dosey, Timothy L ^b   Qi, Junlin ^b   Fischer, Karin A ^b   Hoofnagle, Andrew N ^a   Sadilek, Martin ^b   Chamberlain, Jeffrey S ^b   Ruohola Baker, Hannele ^b   Reyes, Morayma ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 84880886286     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-3-20     Document Type: Article

References (79)

1. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7. 10.1016/j.pediatrneurol.2006.09.016, 17162189.
2. Mendell JR, Rodino-Klapac LR, Malik V. Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J Child Neurol 2010, 25:1145-1148. 10.1177/0883073810371005, 3674570, 20498331.
3. Palmieri B, Tremblay JP, Daniele L. Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant 2010, 14:813-819. 10.1111/j.1399-3046.2010.01377.x, 20963914.
4. Rapizzi E, Donati C, Cencetti F, Nincheri P, Bruni P. Sphingosine 1-phosphate differentially regulates proliferation of C2C12 reserve cells and myoblasts. Mol Cell Biochem 2008, 314:193-199. 10.1007/s11010-008-9780-y, 18454302.
5. Danieli-Betto D, Peron S, Germinario E, Zanin M, Sorci G, Franzoso S, Sandona D, Betto R. Sphingosine 1-phosphate signaling is involved in skeletal muscle regeneration. Am J Physiol 2010, 298:C550-C558.
6. Bernacchioni C, Cencetti F, Blescia S, Donati C, Bruni P. Sphingosine kinase/sphingosine 1-phosphate axis: a new player for insulin-like growth factor-1-induced myoblast differentiation. Skelet Muscle 2012, 2:15. 10.1186/2044-5040-2-15, 3439699, 22788716.
7. Bruni P, Donati C. Pleiotropic effects of sphingolipids in skeletal muscle. Cell Mol Life Sci 2008, 65:3725-3736. 10.1007/s00018-008-8236-6, 18668202.
8. Loh KC, Leong WI, Carlson ME, Oskouian B, Kumar A, Fyrst H, Zhang M, Proia RL, Hoffman EP, Saba JD. Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS One 2012, 7:e37218. 10.1371/journal.pone.0037218, 3351440, 22606352.
9. Pantoja M, Fischer KA, Ieronimakis N, Reyes M, Ruohola-Baker H. Genetic elevation of Sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila. Development 2013, 140:136-146. 10.1242/dev.087791, 23154413.
10. Bagdanoff JT, Donoviel MS, Nouraldeen A, Tarver J, Fu Q, Carlsen M, Jessop TC, Zhang H, Hazelwood J, Nguyen H, Baugh SD, Gardyan M, Terranova KM, Barbosa J, Yan J, Bednarz M, Layek S, Courtney LF, Taylor J, Digeorge-Foushee AM, Gopinathan S, Bruce D, Smith T, Moran L, O'Neill E, Kramer J, Lai Z, Kimball SD, Liu Q, Sun W, et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem 2009, 52:3941-3953. 10.1021/jm900278w, 19489538.
11. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (New York, NY 2005, 309:1735-1739.
12. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995, 118:959-964. 10.1093/jb/118.5.959, 8749313.
13. Ieronimakis N, Balasundaram G, Rainey S, Srirangam K, Yablonka-Reuveni Z, Reyes M. Absence of CD34 on murine skeletal muscle satellite cells marks a reversible state of activation during acute injury. PLoS One 2008, 5:e10920.
14. Grabski AD, Shimizu T, Deou J, Mahoney WM, Reidy MA, Daum G. Sphingosine-1-phosphate receptor-2 regulates expression of smooth muscle alpha-actin after arterial injury. Arterioscler Thromb Vasc Biol 2009, 29:1644-1650. 10.1161/ATVBAHA.109.191965, 2746263, 19608972.
15. Au CG, Butler TL, Sherwood MC, Egan JR, North KN, Winlaw DS. Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. Int J Exp Pathol 2011, 92:57-65. 10.1111/j.1365-2613.2010.00750.x, 3052757, 21121985.
16. Danieli-Betto D, Germinario E, Esposito A, Megighian A, Midrio M, Ravara B, Damiani E, Libera LD, Sabbadini RA, Betto R. Sphingosine 1-phosphate protects mouse extensor digitorum longus skeletal muscle during fatigue. Am J Physiol 2005, 288:C1367-C1373.
17. Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol 2002, 161:2263-2272. 10.1016/S0002-9440(10)64502-6, 1850914, 12466140.
18. Gregorevic P, Plant DR, Lynch GS. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004, 30:295-304. 10.1002/mus.20082, 15318340.
19. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem 2001, 292:287-295. 10.1006/abio.2001.5063, 11355863.
20. Oliver IT. A spectrophotometric method for the determination of creatine phosphokinase and myokinase. Biochem J 1955, 61:116-122. 1215753, 13260184.
21. Kiernan J. Histological and Histochemical Methods: Theory and Practice 2008, New York: Cold Spring Harbor Laboratory Press, 4.
22. Clever JL, Sakai Y, Wang RA, Schneider DB. Inefficient skeletal muscle repair in inhibitor of differentiation knockout mice suggests a crucial role for BMP signaling during adult muscle regeneration. Am J Physiol 2010, 298:C1087-C1099.
23. Chapman VM, Miller DR, Armstrong D, Caskey CT. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 1989, 86:1292-1296. 10.1073/pnas.86.4.1292, 286674, 2919177.
24. Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995, 129:97-105. 10.1016/0022-510X(94)00276-T, 7608742.
25. Zhou J, Saba JD. Identification of the first mammalian sphingosine phosphate lyase gene and its functional expression in yeast. Biochem Biophys Res Commun 1998, 242:502-507. 10.1006/bbrc.1997.7993, 9464245.
26. Mendel J, Heinecke K, Fyrst H, Saba JD. Sphingosine phosphate lyase expression is essential for normal development in Caenorhabditis elegans. J Biol Chem 2003, 278:22341-22349. 10.1074/jbc.M302857200, 12682045.
27. d'Albis A, Couteaux R, Janmot C, Roulet A, Mira JC. Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals. Myosin isoform analysis. E J Biochem 1988, 174:103-110.
28. Yan Z, Choi S, Liu X, Zhang M, Schageman JJ, Lee SY, Hart R, Lin L, Thurmond FA, Williams RS. Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem 2003, 278:8826-8836. 10.1074/jbc.M209879200, 12477723.
29. Mouisel E, Vignaud A, Hourde C, Butler-Browne G, Ferry A. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice. Muscle Nerve 2010, 41:809-818. 10.1002/mus.21624, 20151467.
30. Ieronimakis N, Balasundaram G, Rainey S, Srirangam K, Yablonka-Reuveni Z, Reyes M. Absence of CD34 on murine skeletal muscle satellite cells marks a reversible state of activation during acute injury. PLoS One 2010, 5:e10920. 10.1371/journal.pone.0010920, 2880004, 20532193.
31. Glesby MJ, Rosenmann E, Nylen EG, Wrogemann K. Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle Nerve 1988, 11:852-856. 10.1002/mus.880110809, 3173410.
32. Salimena MC, Lagrota-Candido J, Quirico-Santos T. Gender dimorphism influences extracellular matrix expression and regeneration of muscular tissue in mdx dystrophic mice. Histochem Cell Biol 2004, 122:435-444.
33. Cros D, Harnden P, Pellissier JF, Serratrice G. Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. J Neurol 1989, 236:43-47. 10.1007/BF00314217, 2915226.
34. Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011, 138:3625-3637. 10.1242/dev.064162, 3152921, 21828091.
35. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Munoz-Canoves P. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 2011, 1:21. 10.1186/2044-5040-1-21, 3156644, 21798099.
36. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 2002, 200:69-79. 10.1046/j.0021-8782.2001.00008.x, 1570883, 11837252.
37. Peter AK, Crosbie RH. Hypertrophic response of Duchenne and limb-girdle muscular dystrophies is associated with activation of Akt pathway. Exp Cell Res 2006, 312:2580-2591. 10.1016/j.yexcr.2006.04.024, 16797529.
38. Halevy O, Piestun Y, Allouh MZ, Rosser BW, Rinkevich Y, Reshef R, Rozenboim I, Wleklinski-Lee M, Yablonka-Reuveni Z. Pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewal. Dev Dyn 2004, 231:489-502. 10.1002/dvdy.20151, 15390217.
39. Reimann J, Irintchev A, Wernig A. Regenerative capacity and the number of satellite cells in soleus muscles of normal and mdx mice. Neuromuscul Disord 2000, 10:276-282. 10.1016/S0960-8966(99)00118-2, 10838255.
40. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 2000, 102:777-786. 10.1016/S0092-8674(00)00066-0, 11030621.
41. Heo K, Park KA, Kim YH, Kim SH, Oh YS, Kim IH, Ryu SH, Suh PG. Sphingosine 1-phosphate induces vascular endothelial growth factor expression in endothelial cells. BMB Rep 2009, 42:685-690. 10.5483/BMBRep.2009.42.10.685, 19874715.
42. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, Kuwabara A, Kanda T, Kobayashi I, Ohta H, Ui M, Okajima F. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 2000, 348(Pt 1):71-76. 1221037, 10794715.
43. Rikitake Y, Hirata K, Kawashima S, Ozaki M, Takahashi T, Ogawa W, Inoue N, Yokoyama M. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol 2002, 22:108-114. 10.1161/hq0102.101843, 11788469.
44. Yeh HI, Dupont E, Coppen S, Rothery S, Severs NJ. Gap junction localization and connexin expression in cytochemically identified endothelial cells of arterial tissue. J Histochem Cytochem 1997, 45:539-550. 10.1177/002215549704500406, 9111232.
45. Beenakker EA, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol 2005, 9:387-393. 10.1016/j.ejpn.2005.06.004, 16102988.
46. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001, 535:591-600. 10.1111/j.1469-7793.2001.00591.x, 2278782, 11533147.
47. Nagata Y, Partridge TA, Matsuda R, Zammit PS. Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J Cell Biol 2006, 174:245-253. 10.1083/jcb.200605028, 2064184, 16847102.
48. Frank SJ, Engel I, Rutledge TM, Letourneur F. Structure/function analysis of the invariant subunits of the T cell antigen receptor. Semin Immunol 1991, 3:299-311.
49. Tajbakhsh S, Bober E, Babinet C, Pournin S, Arnold H, Buckingham M. Gene targeting the myf-5 locus with nlacZ reveals expression of this myogenic factor in mature skeletal muscle fibres as well as early embryonic muscle. Dev Dyn 1996, 206:291-300. 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D, 8896984.
50. Beauchamp JR, Heslop L, Yu DS, Tajbakhsh S, Kelly RG, Wernig A, Buckingham ME, Partridge TA, Zammit PS. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol 2000, 151:1221-1234. 10.1083/jcb.151.6.1221, 2190588, 11121437.
51. Day K, Shefer G, Richardson JB, Enikolopov G, Yablonka-Reuveni Z. Nestin-GFP reporter expression defines the quiescent state of skeletal muscle satellite cells. Dev Biol 2007, 304:246-259. 10.1016/j.ydbio.2006.12.026, 1888564, 17239845.
52. Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S. Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 2009, 78:743-768. 10.1146/annurev.biochem.78.072407.103733, 19231986.
53. Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell 1999, 10:1179-1190. 10.1091/mbc.10.4.1179, 25247, 10198065.
54. Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V, Hwang SI, Han DK, Hla T. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest 2011, 121:2290-2300. 10.1172/JCI45403, 3104755, 21555855.
55. Estrada R, Wang L, Jala VR, Lee JF, Lin CY, Gray RD, Haribabu B, Lee MJ. Ligand-induced nuclear translocation of S1P(1) receptors mediates Cyr61 and CTGF transcription in endothelial cells. Histochem Cell Biol 2009, 131:239-249. 10.1007/s00418-008-0521-9, 2861785, 18936953.
56. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res 2001, 89:496-502. 10.1161/hh1801.096338, 11557736.
57. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, Berrebi-Bertrand I. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 2001, 33:1589-1606. 10.1006/jmcc.2001.1433, 11549339.
58. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3:1014-1019. 10.1038/ncb1101-1014, 11715023.
59. Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, Zlotchenko E, Stitt TN, Economides AN, Yancopoulos GD, Glass DJ. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004, 24:9295-9304. 10.1128/MCB.24.21.9295-9304.2004, 522257, 15485899.
60. Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res 2002, 35:305-313.
61. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 1999, 8:855-861. 10.1093/hmg/8.5.855, 10196375.
62. Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, Goolsby H, Watkins SC, Cox GA, Brown RH. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004, 13:1999-2010. 10.1093/hmg/ddh212, 15254015.
63. Millay DP, Maillet M, Roche JA, Sargent MA, McNally EM, Bloch RJ, Molkentin JD. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 2009, 175:1817-1823. 10.2353/ajpath.2009.090107, 2774048, 19834057.
64. Han R, Rader EP, Levy JR, Bansal D, Campbell KP. Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice. Skelet Muscle 2011, 1:35. 10.1186/2044-5040-1-35, 3287108, 22132688.
65. Aoki M, Takahashi T. [Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)]. Rinsho shinkeigaku 2005, 45:938-942. Article in Japanese.
66. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002, 28:461-470. 10.1046/j.1365-2990.2002.00417.x, 12445162.
67. Farini A, Sitzia C, Navarro C, D'Antona G, Belicchi M, Parolini D, Del Fraro G, Razini P, Bottinelli R, Meregalli M, Torrente Y. Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model. Exp Cell Res 2012, 318:1160-1174. 10.1016/j.yexcr.2012.03.010, 22465227.
68. Mokhtarian A, Lefaucheur JP, Even PC, Sebille A. Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration. J Appl Physiol 1999, 86:924-931.
69. Torres LF, Duchen LW. The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 1987, 110(Pt 2):269-299.
70. DiMario JX, Uzman A, Strohman RC. Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. Dev Biol 1991, 148:314-321. 10.1016/0012-1606(91)90340-9, 1936568.
71. Ikeda M, Kihara A, Igarashi Y. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the cytosol. Biochem Biophys Res Commun 2004, 325:338-343. 10.1016/j.bbrc.2004.10.036, 15522238.
72. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257. 10.1126/science.1176709, 2850596, 19729656.
73. Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, Ragone G, Pescatori M, Zaccagnini G, Antonini A, Minetti G, Martelli F, Piaggio G, Gallinari P, Steinkuhler C, Clementi E, Dell'Aversana C, Altucci L, Mai A, Capogrossi MC, Puri PL, Gaetano C. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 2008, 105:19183-19187. 10.1073/pnas.0805514105, 2614736, 19047631.
74. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004, 6:673-684. 10.1016/S1534-5807(04)00107-8, 15130492.
75. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol 2009, 297:C1124-C1132.
76. Zammit PS, Partridge TA. Sizing up muscular dystrophy. Nat Med 2002, 8:1355-1356. 10.1038/nm1202-1355, 12457175.
77. Smyth SS, Sciorra VA, Sigal YJ, Pamuklar Z, Wang Z, Xu Y, Prestwich GD, Morris AJ. Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J Biol Chem 2003, 278:43214-43223. 10.1074/jbc.M306709200, 12909631.
78. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897. 10.1038/nrd3248, 21031003.
79. Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, Peyruchaud O, Macdonald TL, Lynch KR. Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 2011, 338:879-889. 10.1124/jpet.111.181552, 3164350, 21632869.